Effectiveness of the medicinal plant R019 in the treatment of HIV infection: An observational study by Allabi, Aurel Constant et al.
Available at:
http://hdl.handle.net/2078.1/164051
[Downloaded 2019/04/19 at 03:29:41 ]
"Effectiveness of the medicinal plant R019 in the
treatment of HIV infection: An observational study"
Allabi, Aurel Constant ; Dossa, Richi ; Djeigo, Julien Gaudence ;
Yombi, Jean Cyr ; Diombo, Kouma ; Giambattista, Priuli ; Bigot, André
Abstract
This study aims to evaluate the in vivo antiviral, immunologic, clinical effects
and safety of a supposedly anti-HIV phytotherapy, code-named R019 used for
the treatment of HIV/AIDS. This is an open observational study, which involved
32 HIV-1 infected patients, who were followed over a 3-month period. The
efficacy evaluation was based on CD4 count, determination of viral load and
clinical status. The safety evaluation was based on renal and liver function tests,
fasting lipid and glycaemia levels as well as the frequency of other adverse
events. The CD4 values increased significantly (mean±SD, 99.03±22.87 cells/μL;
P&lt;0.001), as well as Weight and Karnofsky score (2.94±0.67 kg, p&lt;0.001;
4.9, p=0.005 respectively). The viral load decreased significantly (0.91±0.12 log
viral load, P&lt;0.0001). R019 did not impair renal or liver functions. Improvement
of creatinine clearance was observed (p=0.02). Hemoglobin levels increased
(0.38±0.16 gr/dL) whereas cholesterol and glucose...
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Yombi, Kouma Diombo, André Bigot and Priuli Giambattista 
 
ABSTRACT  
 
 This study aims to evaluate the in vivo antiviral, immunologic, clinical effects and 
safety of a supposedly anti-HIV phytotherapy, code-named R019 used for the treatment of 
HIV/AIDS.  This is an open observational study, which involved 32 HIV-1 infected patients, 
who were followed over a 3-month period. The efficacy evaluation was based on CD4 count, 
determination of viral load and clinical status. The safety evaluation was based on renal and 
liver function tests, fasting lipid and glycaemia levels as well as the frequency of other adverse 
events. The CD4 values increased significantly (mean±SD, 99.03±22.87 cells/µL; P<0.001), as 
well as Weight and Karnofsky score (2.94±0.67 kg, p<0.001; 4.9, p=0.005 respectively). The 
viral load decreased significantly (0.91±0.12 log viral load, P<0.0001). R019 did not impair 
renal or liver functions. Improvement of creatinine clearance was observed (p=0.02). 
Hemoglobin levels increased (0.38±0.16 gr/dL) whereas cholesterol and glucose levels 
decreased under R019 treatment (p=0.031, p=0.018 respectively). Main adverse effects were 
recorded: polyuria (40.5%), drowsiness (21.4%), orexis (19.1%). Immunological, anti-viral and 
clinical status improved under R019 treatment and a good safety profile was observed for this 
compound. Further studies would be required to optimize its efficacy and to define its 
appropriateness for the treatment of HIV disease. 
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 INTRODUCTION 
 
 HIV/AIDS continues to be one of the public health concerns for policy makers and the 
entire community in the Republic of Benin. Available records show that the prevalence rate of 
HIV infection in 1990 was 0.3%, increasing to around 2% in 2002, with some regional variations. 
Current projections indicate that by 2010, the number of people living with HIV would be about 
79,000 in Benin (Ministère de la Santé, 2004). Since 2006, a predicted quarterly growth of 250 
patients has risen to the current figure of around 700. Based on this projection, 4,500 patients were 
meant to be supplied with antiretroviral (ARVs) in 2004, increasing by 1,000 patients per year 
until 2010. This has generated a shortfall that needs to be urgently addressed. Despite the efforts of 
governments and development partners, a considerable proportion of people living with 
HIV/AIDS, still have limited access to antiretroviral (ARV) medicines. This state of affairs led to 
the “3 by 5” initiative, which was launched in 2003 by the World Health Organization (WHO) and 
the Joint United Nations Program on HIV/AIDS’s (UNAIDS, as a global TARGET to provide 
three million people living with HIV/AIDS in low- and middle-income countries with life-
prolonging antiretroviral treatment by the end of 2005 (WHO, 2005). 
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 Although, the initiative had not met its set target as of 
2005, there was a significant increase in the number of people 
receiving ARV therapy, as well as renewed commitment to 
expanding prevention activities and strengthening health systems. 
Moreover, the initiative was instrumental in generating increased 
financial and technical support to deal with the pandemic.  
Several other challenges exist to hamper the fight against 
the pandemic. These include lack of readily available reagents for 
the detection of new cases, limited access to ARVs (WHO Benin, 
2007), lack of trust in health care professionals, shortage of 
qualified health workers, the limitation of the criteria for inclusion 
in highly active antiretroviral therapy (HAART) regimen, and fear 
of stigmatization due to ARVs side-effects (MS, Benin, 2004) 
(Ministère de la Santé, 2004). In addition, most ARV treatment 
sites (40 testing sites based in 12 departments) are located in towns 
and urban centers, further hampering access for HIV-positive 
patients living in rural areas. Interestingly, support for HIV patients 
is still entirely dependent on donor funds (Zannou, 2006), which 
are inadequate to meet the rising demand. 
Due to sociocultural beliefs, 60-80% of the population 
including many HIV patients, resort to traditional medicine (WHO, 
(Organisation Mondiale de la Santé (OMS) 2002-2005);). The use 
of phytotherapy is therefore frequent in HIV patients, irrespective 
of scientific validation of such shown medicines.  
The present study was therefore designed to evaluate the 
effectiveness of medicinal plant coded R019, commonly 
administered to HIV patients who are not yet eligible for 
antiretroviral therapy at the TANGUIETA hospital (WHO, 2006) 
(WHO, 2006).  
R019, known as “kinkeliba” in the Republic of Benin and 
other West African countries, is commonly used for the treatment 
of numerous ailments such as infection, diarrhea, fever, and bowel 
dysfunction (Nikiema et al., 2004b; Ogan, 1972; Bassene, et al., 
1986). The plant is also claimed to have cardiovascular and 
diuretic properties. Over the past twenty years, R019 has been 
evaluated for its antiviral (Ferrea et al., 2004; Pengsuparp et al., 
1995; Cohen, et al., 1996; Ferrea, et al., 1993b; Ferrea, et al., 
1993a), antimalarial, antibacterial, anti-inflammatory (Olajide, et 
al., 2003) and diuretic properties.  
There are no clinical studies on its anti-HIV effects, 
probably due to the complex methodological and practical 
challenges associated with the clinical evaluations of traditional 
medicines such as R019. The above reason, together with the long 
history of use, led to the choice of an observational study, which is 
a relatively simple and inexpensive approach to assess the 
effectiveness of R019, with the expected outcomes being its 
immunological and anti-viral actions, its ability to increase the 
weight of the patients and to enhance their quality of life, as well as 
any associated adverse events.  
 
MATERIALS AND METHODS 
 
 The study, which was carried out between March 2009 
and January 2010, involved regular self-administration of 
measured doses of R019 to HIV patients, who were not eligible for 
HAART, in a single centre, prospective, non-interventional 3-
month observational study. Written informed consent was obtained 
from all patients, and the study protocol was approved by a Review 
Board and an independent Ethics Committee at the study centre 
(Letter’s number: 0121-2009). 
 
Plant material 
 Leaves of R019 were collected in the Tanguieta district, 
Republic of Benin throughout one year. The plant was identified 
by Gaudence Djeigo of the Faculty of Agricultural Sciences of the 
Université d’Abomey-Calavi. The voucher specimen X123UAC 
was deposited in the herbarium of the University. The plant 
material was dried at room temperature and reduced to powder 
using a Thomas Scientific mill with a delivery tube of 2 mm 
diameter. The powder was then stored in a freezer at -10°C. Five 
grams of the powder were used to prepare one liter of decoction. 
For quality control purposes, the organoleptic characteristics of 
R019 powder were assessed, and this gave a green powder with a 
greasy smell. Six classes of chemical compounds were identified in 
the pure R019 (R019)-based extract: tannins, anthocyanins, 
leucoanthocyanins, and reducing sugars as the major compounds, 
whereas flavonoids and essential oils were present in small 
amounts.   
 
Patients 
Inclusion criteria 
 To be included in the study, all patients had to undergo an 
initial clinical and laboratory assessment. They were also screened 
for HBV surface antigen and HCV antibody.  
HIV-1 infected patients were identified by ELISA and 
confirmed by HIV-1 RNA PCR. Patients included in the cohort 
were aged between 18 and 55 years, with CD4+ T cell count 
between 200 and 500 cells/ µL, and naive for ARV. The patients 
with CD4>200 cells/µL were not eligible for ARV, according to 
local treatment guidelines in Benin.  
Exclusion criteria: Patients with a history of severe psychiatric 
illness or any history of a chronic illness, such as cardiopulmonary 
disorder, were excluded from the study.  
 
Treatment and Assessments 
Dosage and administration 
 R019 was prescribed to the patients on a regular basis. 
During 3-month follow up period every day, patients received one 
liter of decoction of R019, to drink between the 08.00 and 16.00 
hours in an unsupervised fashion.  
 
Follow up 
 Each patient was followed over a three month period. 
Study visits were scheduled at Day 0 (D0), D14, D30, D60 and 
D90.  
 
Clinical assessment 
 Study evaluations included physical examination; 
assessment of vital signs, symptoms, and review of adverse events 
reported by the patients. 
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Laboratory assessments 
 Laboratory analysis were performed at D0, D30 and D90 
(serum chemistry and hematology tests, CD4 cell counts by flow 
cytometry and HIV-1 RNA level by quantitative reverse-
transcriptase-polymerase-chain reaction (PCR) assay). A fasting 
metabolic assessment (i.e., analysis of total cholesterol, high-
density lipoprotein, low-density lipoprotein, triglycerides, glucose), 
and orthostatic blood-pressure monitoring were performed at D0, 
D14, D30 and D90. The evaluation of efficacy was based on the 
change in viral load (measured as log 10-transformed copies/mL), 
change in CD4 cell counts and clinical status (weight, BMI and 
Karnofsky index as a scoring of physical performance at each 
visit). Safety was assessed using total cholesterol [TC], 
triglycerides, liver enzymes (alanine aminotransferase [ALT], 
aspartate aminotransferase [AST], Gamma-glutamyltranspeptidase 
[GGT]) and bilirubin levels at D0, D30 and D90 and the frequency 
of adverse events during treatment with R019. The renal function 
was evaluated by measuring serum creatinine and creatinine 
clearance (using Cockroft-Gault formula). Adverse events (AEs) 
were defined as all disorders of well being, subjective and 
objective disease symptoms reported by patient, significant 
laboratory changes, concomitant illnesses, and accidents (death or 
hospitalizations) occurring during the course of the study. AEs 
were evaluated by the investigators based on severity (mild, 
moderate or serious). A serious adverse event (SAE) was defined 
as an event which is fatal or life-threatening, results in persistent or 
significant disability/incapacity, constitutes a congenital 
anomaly/birth defect, and requires inpatient hospitalization or 
prolongation of existing hospitalization (FDA, 2010).  Adverse 
events were documented during clinic visits. They were also 
recorded after visits, either by self-reporting by the subject or by 
detection of clinical signs and changes in laboratory parameters by 
the physician.  
 
Statistics 
 All patients participated in the cohort were included in the 
analysis. Descriptive summary statistics were used for this cohort 
analysis, describing changes in CD4+ cell count and viral load from 
baseline, the type and frequency of adverse events observed, and 
changes in safety-relevant laboratory parameters. For continuous 
variables, the following statistics were calculated: mean; standard 
deviation, median, minimum, maximum and 95% interval 
confidence of mean. For categorical variables, the number of 
values in each category and percentage of the values with regard to 
the number of patients in the study population were calculated. 
Explorative statistical methods were used with regard to the 
efficacy endpoints and changes in safety-relevant laboratory 
parameters. Changes from baseline were tested for significance 
using the Wilcoxon signed-rank test. The sample size was 
determined using the sampsi function in STATA version 9 
(STATA Corp., College Station, TX, USA). A change in CD4 
counts of 50 cell/microliter was considered clinically significant. 
This study needed 32 patients to detect a significant change of 50 
cells CD4+/microlitre, with a standard deviation of 100 cells 
CD4+/microlitre with a power of 80%.  
 
RESULTS 
 
 Thirty two patients were included in the study. There were 
no dropouts. Baseline characteristics including demographic data 
are summarized in Table I. Four (12.5%) patients were infected 
with hepatitis B at the start of the study and 1 (3.1%) patient had 
co-infection with hepatitis C. No patient had both hepatitis (B and 
C). A total of 20 (62.5%) of the patients were at stage 2 and the 
remaining, i.e. 37.5%, were at stage 3 according to WHO 
classification. 
 
Table. 1: Patients’ baseline characteristics. 
 
Sex: n (%)  
     Male  12(37.5) 
     Female 20(62.5) 
Age (years)  
     Mean 31.13 
     Range 18-55 
Weight (kg)  
     Mean 53.53 
     Range 34-75 
Nationalities: n (%)   
     Beninese 30(93.7) 
     Togolese 1(3.1) 
     Guineans 1(3.1) 
CD4 count (cells/µL)  
     Median 274 
     Range 208-500 
Viral load (log10 copies/mL)  
     Mean  4.93 
     Range  
 Stage (WHO) 
      1 and 2 
      3 and 4 
      HCV n (%) 
      HBV n (%)                                                                         
3.87-5.00 
 
20(62.5) 
12(37.5) 
1(3.1) 
4(12.5) 
 
CD4 cell count 
 At initiation the mean CD4 cell count was 289 cells/mm3 
and the majority of the patients   (78.125%)   had an initial CD4 
count below 350 cells/µL (Table 2). At D90, the mean CD4 cell 
count was 387.84, i.e an increase by 99 cells/mm3 (p=0.010). The 
CD4 cell count decreased only in one patient and remained stable 
in eight patients. 
 
Viral load (VL) 
 Median log (VL) at baseline was 4.91; after 3 months of 
treatment a decrease of 0.91 was seen (P=0.000). However, no 
patient had an undetectable viral load (< 50 copies/ml) at D90 
(Table 2).  
 
Health status 
 The mean values of BMI of patients at different follow-up 
times were normal. However, a significant increase was noted in 
these values (p <0.040) (Table 2). The Karnofsky index of the 
patients increased at D30 and D90 and showed significant 
improvement at D90 compared to D0 (Table 2). 
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Laboratory assessments 
Hemoglobin 
 Treatment with R019 did not adversely affect hemoglobin 
levels. No decrease hemoglobin rate among patients was observed 
(Table 3). In contrast, the hemoglobin level at D90 increased 
significantly compared to that of D0 (p = 0.02).  Red blood cell 
count was not affected by the treatment. The values obtained at 
different times of follow-up were not significantly different from 
each other (p> 0.31). Leukocyte values also remained unchanged. 
 
Liver enzymes 
 AST or ALT were not adversely affected. Instead, there 
was a significant decrease in the level of the enzymes between at 
D30, remained stable at D90. A significant improvement over time 
was observed (Table 3). No statistically significant difference was 
observed for transaminase ALT during the follow-up period (p> 
0.164).  
 
Renal function 
 The renal function (serum creatinine and clearance of 
creatinine) was not affected, but seems improved (serum creatinine 
decreased and clearance of creatinine increased). No significant 
difference was observed between D0 and D30 (p = 0.093) and 
between D30 and D90 (p=0.132). However serum creatinine and 
clearance of creatinine at D90 were significantly improved 
compare to D0 values (p=0.010). 
 
Metabolic assessments 
Lipid changes  The total cholesterol level was significantly reduced significantly at D30 and D90 compared to the pretreatment values. Triglycerides level was not affected  during  follow- up.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glucose level 
 Glucose levels at different follow-up times were normal. 
However a trend towards lower values over follow-up was noticed. 
No significant difference was found between the values at different 
times (D0, D30 and D90) (p>0.145).  
 
Blood pressure measurements 
 Blood pressure was also routinely measured at different 
times of follow-up. The values observed at different times were not 
significantly different. Patients under R019 treatment did not 
develop hypertension or hypotension.  
 
Adverse events (AEs) 
 Adverse events patterns identified with their respective 
frequencies are shown in the table IV. The most frequent adverse 
events were polyuria (53.12%), drowsiness (28.12%) and increased 
appetite (25%). No serious AEs were reported.  
 
Table. 4: Nature and frequency of adverse events. 
 
Adverse Events N(%) 
Headache  1 (3.12) 
Drowsiness  9 (28.12) 
Polyuria  17 (53.12) 
Increased appetite 8 (25) 
Asthenia 3 (9.37) 
Diarrhea 4 (12.5) 
 
DISCUSSION 
 
Clinical, immunological and virological efficacy 
 A potent antiviral activity of R019 was shown here by a 
significant reduction in viral load observed during the three months 
follow up of the AIDS patients. This result is consistent with 
ethno-pharmacological (Nikiema et al., 2004a; Esimone et al., 
2005) and in vitro findings (Pengsuparp et al., 1995; Neamati et 
Table.  2: One and three month changes in CD4 count, viral load, BMI and Karnofsky score in 32 HIV patients on R019 in Benin. 
 
Parameters Day 0 Day 30 Day 90 
 Mean (SD) Range Mean (SD) Range Mean (SD) Range P-value (D90 vs D30) 
CD4 count (cells/ µL) 288 (66) 208-500 340 (94) 215-623 388 (140) 201-776  
p-value (vs D0)   0.002  0.000  0.008 
Viral load (log10/ml) 4.93 (0.65) 3.87-5.7 4.44 (0.65) 3.38-5.7 4.10 (0.55) 3.09-5.7  
p-value (vs D0)   <0.001  <0.001  <0.001 
BMI (kg/m2) 19.9 (2.82) 13.6-26.6 20.9 (3.95) 15.4-30.6 21.4 (3.33) 16.8-33.5  
p-value (vs D0)   0.013  0.000  0.028 
Karnofsky index 93.2 (8.3) 80-100 96.3 (5.5) 80-100 98.1 (4.7) 80-100  
p-value (vs D0)   NS  0.005  0.014 
 
Table 3: One and three month changes in some biological safety parameters in 32 HIV patients on R019 in Benin. 
 
Parameters Day 0 Day 30 Day 90 
 Mean (SD) Range Mean (SD) Range Mean (SD) Range P-value (D90 vs D30) 
Hemoglobin (g/dl) 11.6 (1.76) 8.0-16.2 11.8 (1.76) 8.6-15.3 12.0 (1.71) 8.7-15.5  
p-value (vs D0)   0.023  0.027  NS 
ASAT (U/L) 44.6 (23.2) 18-134 38.2 (14.5) 16-68 38.8 (17.0) 14-94  
p-value (vs D0)   0.018  0.06  NS 
ALAT (U/L) 30.3 (12.7) 11-75 27.3 (11.7) 12-65 29.1 (14.4) 12-81  
p-value (vs D0)   0.032  NS  NS 
Serum creatinine (mg/L) 10.1 (1.62) 7.2-14.9 9.8 (1.60) 7.4-14.7 9.6 (1.48) 7.4-14.6  
p-value (vs D0)   0.019  0.008  NS 
Creatinine clearance (ml/min) 74.8 (18.9) 35.7-113.9 76.9 (19.5) 35.5-116.3 78.1 (17.5) 41.8-113.6  
p-value (vs D0)   0.018  0.008  0.05 
Total Cholesterol (mg/dL) 145.6 (21.7) 103-215 133.8 (18.2) 113-198 134.6 (18.1) 111-200  
p-value (vs D0)   0.02  0.001  NS 
Glycemia (g/L) 0.84 (0.13) 0.69-1.20 0.81 (0.12) 0.64-1.10 0.79 (0.11) 0.55-1.03  
p-value (vs D0)   0.02  0.000  0.000 
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al., 1997; Cohen et al., 1996; Esimone et al., 2005; Phillips et al., 
1991) related to R019. However, none of the patients had an 
undetectable viral load at the end of the study period. The results 
obtained here were comparable with those obtained from 
Maroviroc  in  short  term  monotherapy (Fatkenheuer et al., 2005).  
Compare to historical data, R019 had superior antiretroviral 
activity compared with placebo (-0.82 R019 vs -0.17 placebo) 
(Markowitz et al., 2006). On the other hand, it is really important 
to determine the optimal dosage of R019 using different doses and 
comparing it to placebo. Immunomodulatory effect of R019 was 
clearly demonstrated with the increase of the CD4 cell count by a 
mean of 99 cells. Calabrese et al., in a study of andrographolide in 
HIV infected patients found an increase of 96 CD4 cell counts after 
6 weeks of administration (Calabrese et al., 2000). Our results are 
in line with those seen in many clinical trials on lamuvidine, 
zidovudine, didanosine or ritonavir as well as in monotherapies or 
HAART (Markowitz et al., 2006; Bartlett et al., 1996; Gulick et 
al., 1997) . Recently, Meynard et al in Kalesolo trial comparing 
lopinavir boosted by ritonavir(LPV/r) monotherapy versus current 
treatment continuation for maintenance therapy for HIV-1 
infection found a gain of 98 CD4 cell counts in the LPV/r  
monotherapy arm (Meynard et al., 2010) which is in the same 
range than the value obtained with patients under R019 treatment .  
The respective increase of CD4 and decrease of viral load were 
more noticeable between D0 and D30 compared to D30 and D90. 
The decreased potency during the last period of treatment could be 
explained by the well known process of enzyme saturation or by a 
decrease in compliance. Although, the administration of the 
treatment is not supervised, it is probable that the low level of 
education and literacy of the majority of the patients could cause 
poor compliance and thereby impact negatively on R019’s 
efficacy.  Moreover, the orexigenic effect of R019 may have 
induced some habits such as administration of a lower dose than 
that recommended without notifying the health care professionals. 
In general, less literate patients with low incomes are more likely 
to engage in such practices. Although less probable, we can’t 
ignore the development of resistance to R019 treatment by the 
virus as explanation. Resistance tests have not been done in this 
study.  
 Regarding the clinical efficacy of the remedy, a 
significant increase of weight was observed over time. Similar 
results were obtained also for the Karnofsky index. Significant 
weight increase was obtained between D0 and D90 whereas no 
change was found between D0 and D30. This is similar to result 
obtained by Idigbe et al., in the Nigerian antiretroviral program, in 
2005 (Idigbe et al., 2005). 
 
Tolerability and Safety 
 R019 was found to have better tolerance than ARVs, 
which tend to exhibit a pattern of side effects often requiring the 
discontinuation or modification of the treatment (Calza et al., 
2004; Arribas et al., 2010). In addition, liver function was not 
affected under R019 treatment and there was a noticeable decrease 
in transaminases. This confirms the hepatoprotective property 
previously described for the R019 (Perrey et al., 2004 ). Also, 
rather than the expected increases in baseline fasting total 
cholesterol, LDL cholesterol and triglyceride levels observed with 
ART, R019 shows a good metabolic profile. The total cholesterol 
was reduced significantly and no increase of triglycerides was 
detected. The presence of inositol, tannin and unsaturated fatty 
acids in the R019 would certainly contribute to this effect (Bassene 
et al., 1981; Ogan, 1972). This is a major benefit of R019 
considering the high frequency of metabolic complications 
associated with some combinaison of antiretrovilal regimens 
(Calza et al., 2004). In addition to these pharmacological actions, a 
probable antianaemic property of R019 would also require further 
investigation since a slight increase in the level of hemoglobin was 
observed. This increase in hemoglobin is very interesting because 
several studies (Moore et al., 1998; Sullivan et al., 1998; Mocroft 
et al., 1999; Mekonnen et al., 2003; Srasuebkul et al., 2009), 
showed that anaemia in HIV-infected patients is associated with 
higher rates of disease progression and death, independently of the 
CD4 cell count and other prognostic factors. Besides the 
immunomodulatory and antiviral activities of R019, it appears to 
possess other pharmacological properties such as being 
antioxidant, diuretic, hepatoprotective, orexigenic and 
antihyperglycaemiant (Chika and Bello, 2010), which could be also 
the subject of future investigations. 
 It is worthy of note that despite the promise that R019 
holds as a potential anti-HIV remedy, the limitations of the study 
cannot be ignored. For example, three months of follow-up is too 
short a period to assess the efficacy of a medicinal plant in vivo 
against HIV/AIDS.  
 In spite of these limitations, the huge therapeutic potential 
of the remedy cannot be ignored given the significant improvement 
in all the relevant indicators achieved after three months of 
treatment, which compares favorably with similar results obtained 
with HAART or monotherapy antiretroviral after treatment over 
the same period. The results of this preliminary study are 
significant, not only because of its public health relevance for 
Benin and other countries facing similar health challenges, but also 
because of the increasing need for alternative therapies. Since this 
herbal treatment, as well as other such therapies, are already being 
used as viable, local alternatives, it behooves the scientific 
community to take up the challenge to evaluate their safety and 
efficacy because of their potential impact on global public health.  
Importantly, this study adds to the developing field of “Reverse 
Pharmacology” (Kaya, 2009), in which indigenous knowledge 
combined with a history of safe use and ethno-pharmacological 
efficacy, is exploited as an effective and faster approach to 
discover new medicines.  Following this approach, a novel class of 
integrase inhibitors, the dicaffeoylquinic acids (DCQAs), was 
isolated from medicinal plants in Bolivia (Zhu et al., 1999; 
Robinson et al., 1996).  
 
CONCLUSION 
 
 This preliminary study shows that R019 has an anti-HIV 
activity characterized by an increase in CD4 T cell count and a 
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significant decrease in viral load in HIV1 infected patients after 3 
months of follow-up.  Improvement of health status based on 
weight, BMI and Karnofsky Index, was also observed among 
patients. Furthermore, this study has shown that R019 is well 
tolerated in patients, with no evidence of safety concerns when 
compared with known ADRs of ARVs.  However, more work will 
be needed to standardize the product and its method of preparation 
in order to optimize the level of its active compounds. Thus, more 
data related to its clinical pharmacology are needed to ensure 
potential place among the growing list of effective anti HIV 
therapies. In order to achieve this, randomized, controlled clinical 
trials, and more long-term prospective studies will be required. In 
addition, a more effective strategy will be needed to improve 
compliance and hence the efficacy of R019.   
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